EP regimen
|
WikiDoc Resources for EP regimen |
|
Articles |
|---|
|
Most recent articles on EP regimen |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on EP regimen at Clinical Trials.gov Clinical Trials on EP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on EP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on EP regimen Discussion groups on EP regimen Patient Handouts on EP regimen Directions to Hospitals Treating EP regimen Risk calculators and risk factors for EP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for EP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:EP Regimen; Etoposide-Platinol Regimen; VP Regimen
Overview
EP regimen refers to a regimen consisting of etoposide and cisplatin(Platinol) used to treat small cell[1] and advanced-stage non-small cell lung cancer; also used for the treatment of advanced-stage testicular cancer.[2]
Regimen
EEtoposide (Vepesid)
PCisplatin (Platinol)
Indications
- Small cell[1] and advanced-stage non-small cell lung cancer; also used for the treatment of advanced-stage testicular cancer[3]
References
- ↑ 1.0 1.1 Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T; et al. (2006). "Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer". J Clin Oncol. 24 (13): 2038–43. doi:10.1200/JCO.2005.04.8595. PMID 16648503.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".